Horizon Therapeutics Publ... (HZNP)
NASDAQ: HZNP
· Real-Time Price · USD
116.30
0.00 (0.00%)
At close: Jan 16, 2025, 10:00 PM
Horizon Therapeutics Public Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|
| Actimmune Revenue | 126.08M | 117.16M | 118.83M | 107.3M | 105.56M | 110.99M | 104.62M | 166.67M |
| Actimmune Revenue Growth | +7.61% | -1.41% | +10.75% | +1.65% | -4.89% | +6.09% | -37.23% | n/a |
| B U P H E N Y L Revenue | 7.33M | 7.86M | 10.55M | 9.81M | 21.81M | 20.79M | 304.43M | n/a |
| B U P H E N Y L Revenue Growth | -6.72% | -25.49% | +7.58% | -55.04% | +4.90% | -93.17% | n/a | n/a |
| D U E X I S Product Revenue | 4.9M | 74.02M | 125.33M | 115.75M | 114.67M | 156.48M | n/a | n/a |
| D U E X I S Product Revenue Growth | -93.38% | -40.94% | +8.28% | +0.94% | -26.72% | n/a | n/a | n/a |
| K R Y S T E X X A Revenue | 716.17M | 565.45M | 405.85M | 342.38M | 258.92M | 137.74M | n/a | n/a |
| K R Y S T E X X A Revenue Growth | +26.65% | +39.33% | +18.54% | +32.23% | +87.98% | n/a | n/a | n/a |
| P E N N S A I D Two Percent Revenue | 73.77M | 191.62M | 178.01M | 200.76M | 190.21M | 3.44M | n/a | n/a |
| P E N N S A I D Two Percent Revenue Growth | -61.50% | +7.65% | -11.33% | +5.55% | +5426.03% | n/a | n/a | n/a |
| P R O C Y S B I Revenue | 209.99M | 189.97M | 170.1M | 161.94M | 154.9M | 193.92M | n/a | n/a |
| P R O C Y S B I Revenue Growth | +10.54% | +11.68% | +5.04% | +4.55% | -20.12% | n/a | n/a | n/a |
| Q U I N S A I R Revenue | 1.08M | 1.03M | 698K | 817K | 504K | n/a | n/a | n/a |
| Q U I N S A I R Revenue Growth | +5.25% | +47.28% | -14.57% | +62.10% | n/a | n/a | n/a | n/a |
| R A V I C T I Revenue | 325.65M | 291.94M | 261.62M | 228.75M | 226.65M | n/a | n/a | n/a |
| R A V I C T I Revenue Growth | +11.55% | +11.59% | +14.36% | +0.93% | n/a | n/a | n/a | n/a |
| R A Y O S Revenue | 41.88M | 56.85M | 71.81M | 78.59M | 61.07M | n/a | n/a | n/a |
| R A Y O S Revenue Growth | -26.33% | -20.83% | -8.63% | +28.70% | n/a | n/a | n/a | n/a |
| T E P E Z Z A Revenue | 1.97B | 1.66B | 820.01M | 52.11M | 67.65M | n/a | n/a | n/a |
| T E P E Z Z A Revenue Growth | +18.32% | +102.60% | +1473.73% | -22.97% | n/a | n/a | n/a | n/a |
| U P L I Z N A Revenue | 11.2M | 60.8M | 37.62M | n/a | n/a | n/a | n/a | n/a |
| U P L I Z N A Revenue Growth | -81.58% | +61.63% | n/a | n/a | n/a | n/a | n/a | n/a |
| Vimovo Revenue | 1.85M | 8.4M | n/a | n/a | n/a | n/a | n/a | n/a |
| Vimovo Revenue Growth | -77.96% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 39.53M | 3.21B | 2.19B | 1.29B | 1.19B | 1.03B | 964.04M |
| Non-Us Revenue Growth | -98.77% | +46.50% | +69.54% | +8.93% | +15.59% | +6.48% | n/a |
| United States Revenue | 3.59B | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 434.13M | 453.35M | 372.53M | 397.56M | 398.22M | 372.73M | 398.95M | 360.26M | 355.2M | 331.99M | 276.96M | 226.16M | 222.33M | 247.78M | 185.39M | 172.33M | 167.09M | 172.3M | 174.63M | 161.59M | 176.67M | 179.6M | 167.42M | 153.95M | 181.92M | 174.06M | 200.75M | 132.05M | 133.57M | 141.94M | 125.23M | 106.49M | 135.25M | 73.34M |
| Selling, General, and Administrative Revenue Growth | -4.24% | +21.69% | -6.30% | -0.17% | +6.84% | -6.57% | +10.74% | +1.42% | +6.99% | +19.87% | +22.46% | +1.72% | -10.27% | +33.65% | +7.58% | +3.13% | -3.02% | -1.33% | +8.07% | -8.54% | -1.63% | +7.27% | +8.75% | -15.38% | +4.51% | -13.29% | +52.02% | -1.14% | -5.89% | +13.35% | +17.60% | -21.26% | +84.40% | n/a |
| Research and Development Revenue | 150.03M | 134.15M | 117.53M | 114.06M | 103.25M | 103.13M | 140.91M | 93.55M | 139.83M | 57.69M | 70.88M | 30.21M | 81.07M | 27.21M | 28.56M | 24.57M | 28.31M | 21.73M | 19.68M | 21.17M | 24.27M | 17.64M | 30.87M | 17.93M | 163.1M | 13.06M | 23.96M | 12.81M | 11.21M | 12.72M | 13.69M | 13.07M | 8.92M | 6.18M |
| Research and Development Revenue Growth | +11.84% | +14.14% | +3.04% | +10.47% | +0.11% | -26.81% | +50.63% | -33.10% | +142.38% | -18.61% | +134.66% | -62.74% | +197.95% | -4.72% | +16.22% | -13.22% | +30.33% | +10.37% | -7.02% | -12.76% | +37.52% | -42.84% | +72.20% | -89.01% | +1148.76% | -45.49% | +86.99% | +14.31% | -11.88% | -7.06% | +4.71% | +46.53% | +44.35% | n/a |